NameCruz Merino, Luis de la
DepartmentMedicina
Knowledge areaMedicina
Professional categoryProfesor Titular de Universidad (Pza. V)
E-mailRequest
         
  • No. publications

    73

  • No. visits

    3426

  • No. downloads

    2761


 

Article
Icon

Dendritic cells: the yin and yang in disease progression

Jiménez Cortegana, Carlos; Palomares, Francisca; Alba Jiménez, Gonzalo; Santa-María Pérez, Consuelo; Cruz Merino, Luis de la; Sánchez Margalet, Víctor; López Enriquez, Soledad (Frontiers Media, 2024)
Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically ...
Article
Icon

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

Schadendorf, Dirk; Luke, Jason John; Ascierto, Paolo A.; Long, Georgina V.; Rutkowski, Piotr; Khattak, Adnan; Cruz Merino, Luis de la; Scolyer, Richard A. (BMC, 2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival ...
Article
Icon

Cancer nano-immunotherapy: the novel and promising weapon to fight cancer

García-Domínguez, Daniel J.; López Enriquez, Soledad; Alba Jiménez, Gonzalo; Garnacho Montero, Carmen; Jiménez Cortegana, Carlos; Flores-Campos, Rocío; Cruz Merino, Luis de la; Hajji, Nabil; Sánchez Margalet, Víctor; Hontecillas-Prieto, Lourdes (Mdpi Ag, 2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until ...
Article
Icon

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Piulats, J. M.; Watkins, C.; Costa García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Cruz Merino, Luis de la; Nathan, P. (Oxford University Press, 2024)
Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator’s ...
Article
Icon

Prognostic implications of the residual tumor microenvironment after neoadjuvant chemotherapy in triple-negative breast cancer patients without pathological complete response

Lejeune, Marylène; Reverte, Laia; Sauras, Esther; Gallardo, Noelia; Bosch, Ramón; Roso, Albert; Cruz Merino, Luis de la; López, Carlos (MDPI, 2023)
With a high risk of relapse and death, and a poor or absent response to therapeutics, the triple-negative breast cancer ...
Article
Icon

Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report

Torres-Zurita, Alberto; Vázquez Montero, Lucía; Gallego López, Laura; Mediano Rambla, María Dolores; Cruz Merino, Luis de la (Frontiers Media S.A., 2023)
Nowadays, immune checkpoint inhibitors (ICI) have become the cornerstone of treatment for many tumors, either as monotherapy ...
Article
Icon

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Cruz Merino, Luis de la; Gion, M.; Cruz, J.; Alonso-Romero, J. L.; Quiroga, V.; Moreno, F.; Jiménez Cortegana, Carlos; Sánchez Margalet, Víctor; Rojo, F. (BMC, 2023)
Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and ...
Article
Icon

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Larkin, James; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance Fernandez, Ana M.; Dalle, Stéphane; Cruz Merino, Luis de la; Weber, Jeffrey (American Association Cancer Research, 2023)
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in ...
Article
Icon

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Tibau, Ariadna; Martínez, M. Teresa; Ramos, Manuel; Cruz Merino, Luis de la; Santaballa, Ana; O’Connor, Miriam; Albanell, Joan (Sage Journals, 2023)
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression free survival (PFS) compared ...
Article
Icon

A genetic profling guideline to support diagnosis and clinical management of lymphomas

Sánchez Beato, Margarita; Méndez, Miriam; Criado Guirado, María José; Pedrosa, Lucía; Sequero, Silvia; Yanguas-Casás, Natalia; Cruz Merino, Luis de la; Gálvez, Laura; Llanos, Marta; García, Juan Fernando; Provencio, Mariano (Springer Nature, 2023)
The new lymphoma classifcations (International Consensus Classifcation of Mature Lymphoid Neoplasms, and 5th World Health ...
Article
Icon

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Weber, Jeffrey S.; Schadendorf, Dirk; Del Vecchio, Michele; Larkin, James; Atkinson, Victoria; Schenker, Michael; Cruz Merino, Luis de la; Long, Georgina V. (American Society of Clinical Oncology, 2023)
PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate ...
Article
Icon

Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

Sánchez León, María Luisa; Jiménez Cortegana, Carlos; Silva Romeiro, Silvia; Garnacho Montero, Carmen; Cruz Merino, Luis de la; García-Domínguez, Daniel J.; Hontecillas-Prieto, Lourdes; Sánchez Margalet, Víctor (Mdpi Ag, 2023)
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and ...
Article
Icon

Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

Lejeune, Marylène; Reverte, Laia; Gallardo, Noelia; Sauras, Esther; Bosch, Ramón; Mata, Daniel; Cruz Merino, Luis de la; López, Carlos (Mdpi Ag, 2023)
Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent response to therapeutics and ...
Article
Icon

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

Vázquez Montero, Lucía; Álamo de la Gala, María del Carmen; Cruz Merino, Luis de la (Frontiers Media S.A., 2023)
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in ...
Article
Icon

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant

Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S. A.; Cruz Merino, Luis de la; Slamon, D. J. (Biomed Central LTD, 2023)
Background The phase III MONALEESA-3 trial included frst- (1L) and second-line (2L) patients and demonstrated a signifcant ...
Article
IconIcon

Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization

Jiménez Cortegana, Carlos; Salamanca, Elena; Palazón Carrión, Natalia; Sánchez Jiménez, Flora; Pérez Pérez, Antonio; Vilariño García, Teresa; Gutiérrez Gutiérrez, Belén; Garnacho Montero, José; Cruz Merino, Luis de la; Rodríguez-Baño, Jesús; Sánchez Margalet, Víctor (Frontiers Media S.A., 2023)
SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences ...
Article
Icon

Obesity and Risk for Lymphoma: Possible Role of Leptin

Jiménez Cortegana, Carlos; Hontecillas Prieto, Lourdes; García-Domínguez, Daniel J.; Zapata, Fernando; Palazón Carrión, Natalia; Sánchez León, María Luisa; Tami, Malika; Pérez Pérez, Antonio; Sánchez Jiménez, Flora; Vilariño García, Teresa; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (MDPI, 2022)
Obesity, which is considered a pandemic due to its high prevalence, is a risk factor for many types of cancers, including ...
Article
IconIcon

The effects of dendritic cell-based vaccines in the tumor microenvironment Impact on myeloid-derived suppressor cells

Sánchez León, María Luisa; Jiménez Cortegana, Carlos; Cabrera, Gabriel; Vermeulen, Elba Mónica; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (Frontiers Media, 2022)
Dendritic cells (DCs) are a heterogenous population of professional antigen presenting cells whose main role is diminished ...
Article
Icon

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

Sánchez Molina, Sara; Figuerola Bou, Elisabet; Sánchez Margalet, Víctor; Cruz Merino, Luis de la; Mora, Jaume; Álava Casado, Enrique de; García-Domínguez, Daniel J.; Hontecillas Prieto, Lourdes (MDPI, 2022)
Ewing Sarcoma (EWS) is an aggressive bone and soft tissue tumor that mainly affects children, adolescents, and young adults. ...
PhD Thesis
Icon

Immune Biomarkers In Peripheral Blood In Patients With HER2 Negative Advanced Breast Cancer Treated With A Chemoimmunotherapy Schedule Based On Pembrolizumab And Gemcitabine. – Translational Substudy Of The PANGEA- Breast Cancer Trial (GEICAM/2015-04)

Araujo Fernández, Isabel; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (2022)
Within the last years, immune checkpoint inhibitors (ICI) have constituted a major breakthrough in cancer research. These ...
Article
Icon

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Larkin, James; Weber, Jeffrey; Del Vecchio, Michele; Gogas, Helen; Arance, Ana M.; Dalle, Stephane; Cruz Merino, Luis de la; Mandalá, Mario (Elsevier Science Ltd, 2022)
Abstract Purpose: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled ...
Article
Icon

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

Dang, Chau; Ewer, Michael S.; Delaloge, Suzette; Ferrero, Jean-Marc; Colomer, Ramon; Cruz Merino, Luis de la; Swain, Sandra M. (MDPI, 2022)
BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant–adjuvant pertuzumab–trastuzumab-based therapy for ...
Article
Icon

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Salvador Bofill, Francisco Javier; Moreno Antón, Fernando; Rodríguez Sánchez, César Augusto; Galve Calvo, Elena; Hernando Melia, Cristina; Ciruelos Gil; Cruz Merino, Luis de la; Martín, Miguel (Elsevier, 2022)
Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish ...
Article
Icon

Low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19

Jiménez Cortegana, Carlos; Sánchez Jiménez, Flora; Pérez Pérez, Antonio; Álvarez, Nerissa; Sousa, Alberto; Cantón Bulnes, María Luisa; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (Frontiers Media S.A., 2022)
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, ...
Article
Icon

Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy

Berciano Guerrero, Miguel Ángel; Lavado Valenzuela, Rocío; Moya, Aurelio; Cruz Merino, Luis de la; Toscano, Fátima; Valdivia, Javier; Alba, Emilio (MDPI, 2022)
Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival ...
Article
Icon

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Albanell, J.; Martínez, M. T.; Ramos, M.; O´Connor, M.; Cruz Merino, Luis de la; Santaballa, A.; Rojo, F. (ELSEVIER SCI LTD, 2022)
Background The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor ...
Article
Icon

Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Khattak, Muhammad A.; Luke, Jason J.; Long, Georgina V.; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Dirk; Cruz Merino, Luis de la; Kirkwood, John M. (Elsevier Science Ltd, 2022)
Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected ...
Article
Icon

Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases

Martínez-Chinchilla, Carlos; Vazquez Montero, Lucía; Palazón Carrión, Natalia; Fernández Román, Isabel M.; López Barba, José; Cruz Merino, Luis de la; Rodríguez-Baño, Jesús; Palacios-Baena, Zaira R. (Frontiers Media S.A., 2022)
Immunosuppressant conditions such as hematological malignancies increase the risk of severe acute respiratory syndrome ...
Article
Icon

The complexity of cancer immunotherapy illustrated through skin tumors

Vieco-Martí, Isaac; López Carrasco, Amparo; Cruz Merino, Luis de la; Noguera, R.; Naranjo, Tomás Álvaro (Wichtig Editore, 2022)
Skin tumours are among the cancer types most sensitive to immunotherapy, due to their unique immunogenic features including ...
Article
IconIcon

Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics

García-Domínguez, Daniel J.; Hontecillas Prieto, Lourdes; Palazón Carrión, Natalia; Jiménez Cortegana, Carlos; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (MDPI, 2022)
Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. ...
Article
IconIcon

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Palazón Carrión, Natalia; Martín García-Sancho, Alejandro; Nogales-Fernández, Esteban; Jiménez Cortegana, Carlos; Carnicero-González, Fernando; Ríos Herranz, Eduardo; Sánchez Margalet, Víctor; Rueda Domínguez, Antonio; Cruz Merino, Luis de la (AMER ASSOC CANCER RESEARCH, 2022)
Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide ...
Article
Icon

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

González Cao, María; Mayo de las Casas, Clara; Oramas, Juana; Berciano Guerrero, Miguel Ángel; Cruz Merino, Luis de la; Cerezuela, Pablo; Berrocal, Alfonso (Nature Research, 2021)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with ...
Article
Icon

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

Cruz Merino, Luis de la; Gion, María; Cruz Jurado, Josefina; Quiroga, Vanesa; Andrés, Raquel; Moreno, Fernando; Jiménez Cortegana, Carlos; Sánchez Margalet, Víctor; Rojo, Federico (MDPI, 2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term ...
Article
IconIcon

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial

Jiménez Cortegana, Carlos; Sánchez Martínez, Pilar M.; Palazón Carrión, Natalia; Nogales Fernández, Esteban; Henao Carrasco, Fernando Manuel; García Sancho, Alejandro Martín; Rueda, Antonio; Provencio, Mariano; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (MDPI, 2021)
The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have ...
Article
Icon

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Mandala, Mario; Larkin, James R.; Ascierto, Paolo Antonio; Del Vecchio, Michele; Gogas, Helen; Cruz Merino, Luis de la; Weber, Jeffrey; Lobo, Maurice (BMJ Publishing Group, 2021)
Background Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding ...
Article
Icon

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

Palazón Carrión, Natalia; Jiménez Cortegana, Carlos; Sánchez León, María Luisa; Nieto García, María Adoración; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (Nature Publishing Group, 2021)
Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution ...
Article
Icon

Immunometabolism modulation in therapy

Monferrer, E.; Sanegre, S.; Vieco-Martí, I.; López-Carrasco, A.; Fariñas, F.; Villatoro, A.; Cruz Merino, Luis de la; Álvaro Naranjo, T. (MDPI, 2021)
The study of cancer biology should be based around a comprehensive vision of the entire tumor ecosystem, considering the ...
PhD Thesis
Icon

Análisis del perfil de respuesta inmune en sangre periférica inducido por tratamiento sistémico en el carcinoma de mama avanzado

Sánchez León, María Luisa; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (2021)
La identificación de los diferentes elementos que intervienen en el proceso de inmunoedición, parece clave para explicar ...
Article
Icon

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Cruz Merino, Luis de la; Fasching, P. A. (Elsevier, 2021)
Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) ...
Article
Icon

Leptin, both bad and good actor in cancer

Jiménez Cortegana, Carlos; López-Saavedra, Ana; Sánchez Jiménez, Flora; Pérez Pérez, Antonio; Castiñeiras Fernández, Jesús; Virizuela-Echaburu, Juan A.; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (MDPI, 2021)
Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many ...
Article
Icon

Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature

Sevilla Ortega, Lourdes; Ferrándiz Pulido, Lara; Palazón Carrión, Natalia; Araji Tiliani, Omar; Barquero Aroca, José M.; Moreno Ramírez, David; Cruz Merino, Luis de la (MDPI, 2021)
Background. Isolated limb perfusion (ILP) is a locoregional procedure indicated by the unresectable melanoma of the limbs. ...
Article
Icon

Metabolic classification and intervention opportunities for tumor energy dysfunction

Monferrer, Ezequiel; Vieco-Martí, Isaac; López-Carrasco, Amparo; Fariñas, Fernando; Abanades, Sergio; Cruz Merino, Luis de la; Noguera, Rosa; Naranjo, Tomás Álvaro (MDPI, 2021)
A comprehensive view of cell metabolism provides a new vision of cancer, conceptualized as tissue with cellular-altered ...
Article
Icon

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Jiménez Cortegana, Carlos; Palazón Carrión, Natalia; Martín García-Sancho, Alejandro; Nogales-Fernández, Esteban; Carnicero-González, Fernando; Ríos Herranz, Eduardo; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (BMJ, 2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, ...
Article
Icon

SEOM clinical guideline for the management of cutaneous melanoma (2020)

Majem, M.; Manzano, J. L.; Marquez-Rodas, I.; Mujika, K.; Muñoz-Couselo, E.; Pérez-Ruiz, E.; Cruz Merino, Luis de la; Espinosa, E.; Gonzalez-Cao, M.; Berrocal, A. (Springer Nature, 2021)
Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology ...
Article
Icon

5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study

Ascierto, Paolo Antonio; Dreno, Brigitte; Larkin, James; Ribas, Antoni; Cruz Merino, Luis de la; McArthur, Grant A. (American Association for Cancer Research, 2021)
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and ...
Article
Icon

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

Palazón Carrión, Natalia; Jiménez Cortegana, Carlos; Sánchez-León, M. Luisa; Henao Carrasco, Fernando Manuel; Nogales-Fernández, Esteban; Chiesa, Massimo; Caballero, Rosalía; Rojo, Federico; Nieto García, María Adoración; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (Nature publishing group, 2021)
Identifcation of the diferent elements intervening at the tumor microenvironment seems key to explain clinical evolution ...
PhD Thesis
Icon

Estudio poblaciones celulares en pacientes con linfoma difuso de células B grandes refractarios o en recaída: papel de las células supresoras de origen mieloide en respuesta al tratamiento R2-GDP

Jiménez Cortegana, Carlos; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (2020)
La inmunoedición, que se caracteriza por el escape que realizan las células malignas de la inmunovigilancia antitumoral, ...
PhD Thesis
Icon

Caracterización del perfil inmunitario en sangre periférica y en tejido de carcinoma de mama con tratamiento neoadyuvante. Estudio de su potencial papel pronóstico y predictivo de respuesta

Palazón Carrión, Natalia; Cruz Merino, Luis de la (2020)
Introducción: Los estudios traslacionales permiten una correcta interrelación entre la investigación básica y la clínica. ...
Article
Icon

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report

García, Francisco José Valdivia; Carrión, Natalia Palazón; Cruz Merino, Luis de la (Lippincott Williams & Wilkins, 2020)
Introduction: Leptomeningeal dissemination due to HER2-overexpressing breast cancer is a rare and hard to treat complication ...
Article
Icon

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

Majem, M.; García-Martínez, E.; Martinez, M.; Muñoz-Couselo, E.; Rodriguez-Abreu, D.; Alvarez, R.; Cruz Merino, Luis de la; Lopez-Martin, J. A. (Springer, 2020)
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. ...
Article
Icon

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

Martín, Miguel; Guerrero-Zotano, Ángel; Montero, Ángel; Jara, Carlos; Filipovich, Elena; Rojo, Federico; Cruz Merino, Luis de la; López Tarruella, Sara (2020)
Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 ...
Article
Icon

Integrating the tumor microenvironment into cancer therapy

Sanegre, Sabina; Lucantoni, Federico; Burgos-Panadero, Rebeca; Cruz Merino, Luis de la; Noguera, Rosa; Naranjo, Tomás Álvaro (MDPI, 2020)
Tumor progression is mediated by reciprocal interaction between tumor cells and their surrounding tumor microenvironment ...
Article
Icon

Obesity and Breast Cancer: Role of Leptin

Sánchez Jiménez, Flora; Pérez Pérez, Antonio; Cruz Merino, Luis de la; Sánchez Margalet, Víctor (2019)
Obesity-related breast cancer is an important threat that affects especially post-menopausal women. The link between obesity ...
Article
Icon

Development and validation of a sexual relations satisfaction scale in patients with breast cancer — “SEXSAT-Q”

González Mancha, Rosario; Muñoz, Montserrat; Cruz Merino, Luis de la; Calvo, Lourdes; Cruz, Josefina; Baena-Cañada, Jose Manuel; Ruiz, Miguel Ángel (Biomed Central LTD, 2019)
Purpose: Because the currently available questionnaires to evaluate sexual changes on breast cancer women only address the ...
Article
Icon

Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy

Sánchez Margalet, Víctor; Barco Sánchez, Antonio; Vilariño García, Teresa; Jiménez Cortegana, Carlos; Pérez Pérez, Antonio; Henao Carrasco, Fernando Manuel; Lobo Acosta, María Ángeles; Cruz Merino, Luis de la (Amer Publ Co, 2019)
Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, in particular. Previous ...
Article
Icon

The tumour microenvironment as an integrated framework to understand cancer biology

Burgos-Panadero, Rebeca; Lucantoni, Federico; Gamero-Sandemetrio, Esther; Cruz Merino, Luis de la; Álvaro, Tomás; Noguera, Rosa (Elsevier Ireland Ltd, 2019)
Cancer cells all share the feature of being immersed in a complex environment with altered cell-cell/cell-ex tracellular ...
Article
Icon

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Chacón López-Muñiz, J. I.; Cruz Merino, Luis de la; Gavilá Gregori, J.; Martínez Dueñas, E.; Oliveira, M.; Seguí Palmer, M. A.; Álvarez López, I.; Antolin Novoa, S.; Bellet Ezquerra, M.; López-Tarruella Cobo, S. (Springer, 2019)
Although the metastasic breast cancer is still an incurable disease, recent advances have increased signifcantly the time ...
Article
Icon

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Conroy, Jeffrey M.; Pabla, Sarabjot; Nesline, Mary K.; Glenn, Sean T.; Papanicolau Sengos, Antonios; Burgher, Blake; Cruz Merino, Luis de la; Morrison, Carl (BMC, 2019)
Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune ...
Article
Icon

New horizons in breast cancer: the promise of immunotherapy

Cruz Merino, Luis de la; Palazón Carrión, N.; Henao-Carrasco, F.; Nogales-Fernández, E.; Álamo de la Gala, M.; Vallejo Benítez, A.; Chiesa, M. (Springer, 2019)
Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through ...
Article
Icon

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

González-Rincón, Julia; Méndez, Miriam; Gómez, Sagrario; García, Juan F.; Martín, Paloma; Bellas, Carmen; Cruz Merino, Luis de la; Sánchez-Beato, Margarita (Public Library Science, 2019)
Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation ...
Article
Icon

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Morrison, Carl; Pabla, Sarabjot; Conroy, Jeffrey M.; Nesline, Mary K.; Glenn, Sean T.; Dressman, Devin; Cruz Merino, Luis de la; Ernstoff, Marc S. (BMC, 2018)
Background: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients ...
Article
Icon

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma

Dreno, Brigitte; Ascierto, Paolo A.; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Cruz Merino, Luis de la; Ribas, Antoni (Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo ...
Article
Icon

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

Losa, F.; Iglesias, L.; Pane, M.; Sanz, J.; Nieto, B.; Fuste, V.; Cruz Merino, Luis de la; Concha, A.; Balana, C.; Matias-Guiu, X. (Springer, 2018)
Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which ...
Article
Icon

SEOM clinical guideline for the management of malignant melanoma (2017)

Berrocal, A.; Arance, A.; Castellón, V. E.; Cruz Merino, Luis de la; Espinosa, E.; Cao, M. G.; Larriba, J. L. G.; Marquez-Rodas, I.; Soria, A.; Algarra, S. M. (Springer Int Publ Ag, 2018)
All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when ...
Article
Icon

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Yardley, D.A.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Cruz Merino, Luis de la; Harbeck, N. (Oxford University Press, 2018)
Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity ...
Article
Icon

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF‑mutated melanoma treated in the randomized coBRIM study

Cruz Merino, Luis de la; Di Guardo, Lorenza; Grob, Jean Jacques; Venosa, Alfredo; Larkin, James; McArthur, Grant A.; Dreno, Brigitte (Biomed Central LTD, 2017)
Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the ...
Article
Icon

Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells

Pérez Pérez, Antonio; Sánchez Jiménez, Flora; Vilariño-García, Teresa; Cruz Merino, Luis de la; Virizuela, Juan A.; Sánchez Margalet, Víctor (Public Library Science, 2016)
Obesity is a well-known risk factor for breast cancer development in postmenopausal women. High insulin and leptin levels ...
Article
Icon

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

Rueda Domínguez, A.; Alfaro Lizaso, J.; Cruz Merino, Luis de la; Gumá i Padró, J.; Quero Blanco, C.; Gómez Codina, J.; Llanos Muñoz, M.; Martínez Banaclocha, N.; Rodriguez Abreu, D.; Provencio Pulla, M. (Springer, 2015)
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL ...
Article
Icon

SEOM clinical guidelines in metastatic breast cancer 2015

Gavilá, J.; Lopez-Tarruella, S.; Saura, C.; Muñoz, M.; Oliveira, M.; Cruz Merino, Luis de la; Morales, S.; Alvarez, I.; Virizuela, J. A.; Martin, M. (Springer, 2015)
Metastatic breast cancer is essentially an incurable disease. However, recent advances have resulted in a significant ...
Article
Icon

SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

Provencio Pulla, M.; Alfaro Lizaso, J.; Cruz Merino, Luis de la; Gumá i Padró, J.; Quero Blanco, C.; Gómez Codina, J.; Llanos Muñoz, M.; Martínez Banaclocha, N.; Rodriguez Abreu, D.; Rueda Domínguez, A. (Springer, 2015)
Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph ...
Article
Icon

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer

Martín, Miguel; González-Rivera, Milagros; Morales, Serafín; De La Haba-Rodriguez, Juan; González-Cortijo, Lucía; Manso, Luis; Albanell, Joan; Cruz Merino, Luis de la; Prat, Aleix (Taylor and Francis Group, 2015)
Purpose: Improved understanding of risk of recurrence (ROR) is needed to reduce cases of recurrence and more effectively ...
Article
Icon

New insights into the role of the immune microenvironment in breast carcinoma

Nieto García, María Adoración; Sánchez Margalet, Víctor; Alba Conejo, Emilio; Ruiz Borrego, Manuel; Cruz Merino, Luis de la; Codes Manuel de Villena, Manuel; Henao Carrasco, Fernando Manuel; Vallejo Benítez, Ana; Barco Sánchez, Antonio; Nogales Fernández, Esteban; Brugal Molina, Javier; Martínez Peinado, Antonio; Grueso López, Ana; Casares Lagar, Noelia; Ibáñez Martínez, José (2013)
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast ...
Article
Icon

Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety

Moreno Ramírez, David; Cruz Merino, Luis de la; Ferrándiz Pulido, Lara; Villegas-Portero, Roman; Nieto García, María Adoración (Oxford Academic, 2010)
Background. Isolated limb perfusion (ILP) involves the administration of chemotherapy drugs directly into a limb involved ...